Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Relief therapeutics   /   Relief therapeutics Holding

Aandeel RELIEF THERAPEUTICS N ZSE:RLF.CH, CH1251125998

Laatste koers (chf) Verschil Volume
5,820   -0,020   (-0,34%) Dagrange 5,600 - 5,900 20.151   Gem. (3M) 134K

Relief therapeutics Holding

Volgen
9.104 Posts
Pagina: «« 1 ... 425 426 427 428 429 ... 456 »» | Laatste | Omlaag ↓
  1. eric_k4 23 september 2021 17:24
    dat de overheid geholpen door de eenzijdige, stupide massmedia niet bezig is met de Volkgezondheid, maar denkt haar heil te halen uit massa vaccinatie van zelfs 12 jarigen en < , gvd vaccins die voortijdig zijn goedgekeurd (want pandemie, hahahahaha), wat jij oppert slaat nergens op, domoor!!!
  3. forum rang 10 DeZwarteRidder 24 september 2021 08:46
    quote:

    RodgerRodger schreef op 24 september 2021 07:57:

    relieftherapeutics.com/newsblog/relie...
    Financial Highlights for the Six Months Ended June 30, 2021

    The operating loss amounted to CHF 14.5 million with operating expenses of CHF 15.4 million and a one-time gain of CHF 0.9 million following a third-party debt write-off.
    The period is marked by a significant growth in operating and administrative expenses. Service expenses of CHF 8.3 million (HY2020: CHF 2.9 million) were mainly driven by development activities for RLF-100 and ACER-001. Personnel expenses increased to CHF 3.4 million (HY2020: CHF 0.2 million) as the conduct and oversight of development and administrative projects required additional skilled professionals. Legal and administrative services reached CHF 3.2 million (HY2020: CHF 0.4 million), reflecting the company's need of legal and professional services in relation to its business activities, including the acquisition of APR and AdVita.
    Cash used in operating activities has ramped up to CHF 17.7 million from CHF 3.2 million over the same period last year.
    Net loss for the period was CHF 14.7 million (HY2020: CHF 8.3 million profit)
    Relief acquired APR in exchange for CHF 21.5 million in cash and CHF 45 million in Relief shares. The sellers are also entitled to receive contingent milestone payments of up to CHF 35 million in a combination of cash and Relief shares upon completion of pre-agreed milestones. APR was consolidated in the balance sheet of the group on June 30, 2021, and will contribute to the group's income statement in the second semester 2021.

    Jack Weinstein, Chief Financial Officer and Treasurer of Relief noted: “Relief remains well funded and, based on current programs, we believe we have sufficient reserves to support multiple clinical programs through key value inflection points. Since the beginning of the year to June 30, we bolstered our balance sheet with CHF 30 million in equity financings. We have also been able to take advantage of the flexibility provided by our additional share listing, giving the company, as of September 24, an available cash position of CHF 40 million.”

    Post Reporting Period

    On July 26, 2021, Relief announced that it had entered into a definitive agreement with two U.S. institutional investors to purchase in a private placement an aggregate of 71,428,572 shares of Relief common stock at a purchase price of CHF 0.21 per share, raising aggregate gross proceeds of CHF 15 million.

    On July 27, 2021, the company issued and listed an additional 1 billion common shares. Relief used a total of 413,956,419 shares comprising 135,741,063, 206,786,784 and 71,428,572 shares, respectively, to meet its obligations to the AdVita sellers, the APR sellers and the provision of shares for the CHF 15 million private placement. The remaining shares can be used to support Relief’s current and future business development activities, and to provide additional working capital.

    On July 27, 2021, Relief acquired AdVita in exchange of EUR 25 million in Relief shares and possible future contingent payments of EUR 20 million payable in cash.
    Further details are available in Relief’s Half Year 2021 Report, which is available for download at relieftherapeutics.com/investor-relat...
  4. forum rang 10 DeZwarteRidder 24 september 2021 12:36
    Wereldgezondheidsorganisatie adviseert preventief coronamedicijn
    2 uur geleden
    in BINNENLAND

    GENÈVE - De Wereldgezondheidsorganisatie WHO heeft vrijdag groen licht gegeven voor het gebruik van een preventief geneesmiddel bij patiënten die besmet zijn geraakt met Covid-19. Alleen als patiënten zelf niet voldoende antistoffen hebben aangemaakt, bijvoorbeeld doordat zij afweeronderdrukkende medicatie gebruiken, kan het geneesmiddel gebruikt worden.

    Het gaat om een combinatie van casirivimab en imdevimab van de Amerikaanse farmaceut Regeneron en Zwitserse fabrikant Roche die ervoor zorgt dat het coronavirus minder goed de menselijke cel kan binnendringen. In het Erasmus MC in Rotterdam worden al patiënten behandeld met de combinatie van middelen.

    De methode is niet goedkoop en de WHO roept landen op om bij de fabrikanten aan te dringen op lagere prijzen, schrijft de organisatie in een verklaring. Het is de derde behandelmethode voor Covid-19-patiënten die door de WHO wordt goedgekeurd.
  5. eric_k4 24 september 2021 14:43
    Wederom vissen de kleintjes RLF en Neurorx achter het net met Aviptadil, Zyesami Duidelijk blijkt de voorkeur van FDA en soortgelijken voor Big Pharmas zoals de Amerikaanse farmaceut Regeneron en Zwitserse fabrikant Roche!
    Ik zou in deze wat aanslingerwerk van big brother aandeelhouder GEM verwachten, maar ja? wellicht fungeren zij als rem...?
  6. forum rang 10 DeZwarteRidder 24 september 2021 14:50
    quote:

    eric_k4 schreef op 24 september 2021 14:43:

    Wederom vissen de kleintjes RLF en Neurorx achter het net met Aviptadil, Zyesami Duidelijk blijkt de voorkeur van FDA en soortgelijken voor Big Pharmas zoals de Amerikaanse farmaceut Regeneron en Zwitserse fabrikant Roche!
    Ik zou in deze wat aanslingerwerk van big brother aandeelhouder GEM verwachten, maar ja? wellicht fungeren zij als rem...?
    De harde waarheid begint door te dringen.
  8. forum rang 10 DeZwarteRidder 24 september 2021 18:44
    quote:

    eric_k4 schreef op 24 september 2021 18:30:

    Ik zou in deze wat aanslingerwerk van big brother aandeelhouder GEM verwachten, maar ja? wellicht fungeert GEM als rem...? Wat is jouw idee DZR? svp geen oneliner...
    GEM en Relief hebben een slaande ruzie, dus wat verwacht je van GEM......???

    NRX wordt nog wel gesteund door GEM (voor zo lang het duurt) en daar is Relief niet blij mee.
  9. eric_k4 24 september 2021 20:27

    Wat een mooie nazomeravond smachtend wacht ik op vraag en antwoord, come on DZR!

    DZR: "GEM en Relief hebben een slaande ruzie, dus wat verwacht je van GEM......???"

    Oh sole mio:
    ** wat is je bron voor deze slaande ruzie? GEM heeft onverlet nog steeds 26,3% aandelen RLF...
    ** als ik als grootaandeelhouder ruzie zou hebben, dan zou ik zo snel als mogelijk de boel verlaten, nietwaar, echter GEM blijft, en houdt 26,3% van de aandelen RLF...

    DZR: "NRX wordt nog wel gesteund door GEM (voor zo lang het duurt) en daar is Relief niet blij mee."

    Oh sole mio:
    ** gesteund? waar is de GEM inbreng zichtbaar bij NeuroRX?
    ** niet blij mee? ik begrijp dit snikken niet, help mij een beetje svp?
  11. forum rang 10 DeZwarteRidder 26 september 2021 20:19
    quote:

    eric_k4 schreef op 24 september 2021 20:27:

    Wat een mooie nazomeravond smachtend wacht ik op vraag en antwoord, come on DZR!

    DZR: "GEM en Relief hebben een slaande ruzie, dus wat verwacht je van GEM......???"

    Oh sole mio:
    ** wat is je bron voor deze slaande ruzie? GEM heeft onverlet nog steeds 26,3% aandelen RLF...
    ** als ik als grootaandeelhouder ruzie zou hebben, dan zou ik zo snel als mogelijk de boel verlaten, nietwaar, echter GEM blijft, en houdt 26,3% van de aandelen RLF...
    DZR: "NRX wordt nog wel gesteund door GEM (voor zo lang het duurt) en daar is Relief niet blij mee."
    Oh sole mio:
    ** gesteund? waar is de GEM inbreng zichtbaar bij NeuroRX?
    ** niet blij mee? ik begrijp dit snikken niet, help mij een beetje svp?
    Alle antwoorden staan al op dit draadje.
  13. forum rang 10 DeZwarteRidder 27 september 2021 10:04
    quote:

    eric_k4 schreef op 27 september 2021 09:56:

    DZR, laat mij je duim eens zien, al tijden leeggezogen of niet?

    GEM heeft nimmer geinvesteerd in NRXP, en hier wil ik het bij laten.
    NeuroRx Secures HK$ 750 Million Capital Commitment From The Gem Group for Development of NRX-101
    NRX-101 is the first oral drug awarded FDA Breakthrough Therapy Designation for treatment of Severe Bipolar Depression with Acute Suicidal Ideation

    News provided by
    NeuroRx

    Oct 23, 2019, 08:36 ET
    Share this article

    WILMINGTON, Del., Oct. 23, 2019 /PRNewswire/
    -- NeuroRx, Inc (NeuroRx) announced that it has signed an agreement with GEM Global Yield LLC SCS ("GEM"), the New York based private alternative investment group to provide the NeuroRx with up to HK$ 750 million over a 30 month term following a public listing of NeuroRx's common stock. NeuroRx will use the funds to complete its phase 3 clinical trials and GMP manufacturing requirements in both the US and China for NRX-101, an FDA-designated Breakthrough Therapy in development for suicidal bipolar depression. The company further plans to initiate phase 2 clinical trials in the treatment of Suicidal Post-traumatic Stress Disorder (PTSD) under its Cooperative Research and Development Agreement with the US Department of Veterans Affairs.
    NRX-101 has been awarded FDA Breakthrough Therapy Designation for the treatment of Severe Bipolar Depression with Acute Suicidal Ideation. Today, the only FDA-approved treatment for this condition is electroconvulsive therapy. NeuroRx has initiated phase 3 clinical trials in the United States under an FDA Special Protocol Agreement. For more information see www.clinicaltrials.gov/ct2/show/NCT03...
    NRX-101 has been awarded FDA Breakthrough Therapy Designation for the treatment of Severe Bipolar Depression with Acute Suicidal Ideation. Today, the only FDA-approved treatment for this condition is electroconvulsive therapy. NeuroRx has initiated phase 3 clinical trials in the United States under an FDA Special Protocol Agreement. For more information see www.clinicaltrials.gov/ct2/show/NCT03...

    The initial HK$ 750 Million will be in the form of a capital commitment that allows NeuroRx to draw down funds during the 30-month term by issuing shares of NeuroRx's common stock to GEM (or such persons as it may direct) and subject to share lending arrangement(s) being in place.

    NeuroRx will control the timing and maximum amount of drawdown under this facility and has no minimum drawdown obligation. Concurrent with a public listing of NeuroRx shares, the company will issue warrants to GEM to purchase up to seven and a half per cent (7.5%) of the outstanding common stock of the company on a fully diluted basis. The warrants will have an exercise price per share equal to the lesser of (i) the closing bid price on the first day of public trading or (ii) the pro rata portion of HK$ 1,725 Million valuation for the company. There can be no guarantee that the company will achieve a future public listing in the near future, or at all.

    "This agreement with GEM helps to secure funding for continued growth and development of the company as we attempt to bring a Breakthrough therapy to market for an unmet medical need that kills more than 1000 people worldwide each day," stated Dr. Jonathan Javitt, CEO and Chairman of NeuroRx. Today, patients with suicidal bipolar depression and PTSD have no FDA-approved treatment other than electroconvulsive therapy. We aim to offer a safe, effective alternative.

    About The GEM Group:
    Global Emerging Markets ("GEM") is a $3.4 billion alternative investment group based in Paris, New York and Los Angeles. GEM manages a diverse set of investment vehicles focused on emerging markets that provide the group and its investors with a diversified portfolio of asset classes that span the global private investing spectrum. Each investment vehicle has a different degree of operational control, risk-adjusted return and liquidity profile. The family of funds and investment vehicles provide GEM and its partners with exposure to: Small-Mid Cap Management Buyouts, Private Investments in Public Equities (PIPEs) and select venture investments.

    About NeuroRx, Inc.:
    NeuroRx draws upon 30 years of basic science and clinical expertise in the role of N-methyl-D- aspartate (NMDA), a receptor that regulates human thought processes, particularly depression and suicidality, as well as PTSD. The company is privately funded and led by former senior executives of Johnson & Johnson, BMS, Eli Lilly, Pfizer, and Sunovion. NeuroRx's Board of Directors and Advisors includes Prof. Shoubin Chen, Senior Medical Advisor to the Li Ka Shing Foundation, Hon. Sherry Glied, former Assistant Secretary, U.S. Dept. of Health and Human Services; Lt. Gen. HR McMaster, the 23rd National Security Advisor, Wayne Pines, former Associate Commissioner of the U.S. Food and Drug Administration, and Daniel Troy, former Chief Counsel, U.S. Food and Drug Administration,.
  17. forum rang 10 DeZwarteRidder 27 september 2021 13:44
    Israeli clinical-stage small molecule pharmaceutical company NeuroRx has announced the completion of a merger with Big Rock Partners Acquisition Corporation, a special purpose acquisition (SPAC) company. The company will trade on the NASDAQ as NRXP.

    The deal is estimated to be worth a $1.5 billion valuation, the Haifa-based company said.

    Founded in 2014, NeuroRx is a clinical-stage small molecule pharmaceutical company developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary disease. The company’s two primary medicines are ZYESAMI (aviptadil), an application for COVID-19-related respiratory failure; and NRX-101, which focuses on suicidal bipolar depression and PTSD.

    NeuroRx said it will use the funds from the offering to continue the development of its drugs ZYESAMI and NRX-101. ZYESAMI is the first FDA fast track-designated investigational medicine currently being studied in critically ill COVID-19 patients with respiratory failure. NRX-101 is the first investigational medicine to receive FDA Breakthrough Therapy Designation for patients with suicidal bipolar depression.

    “Today marks a major milestone as we include public investors in our quest to bring innovative medicines to patients at immediate risk of death, who have no currently-approved medicinal therapies. We live by our credo of “Bringing Hope to Life,” said Professor Jonathan Javitt, MD, MPH, founder, CEO and Chairman of the Board, of NeuroRx. “We are indebted to the leaders and shareholders of BRPA who have chosen to support our mission.”

    NRx committed more than $120 million in operating capital from cash on hand, private investment in public equity (PIPE), warrants exercised by the global emerging markets (GEM) global yield fund and a share subscription facility provided by GEM.

    “NRx has dedicated itself to patients whose lives depend upon new, innovative medicines and whose needs have not been addressed by major pharmaceutical companies,” said the Honorable Sherry Glied, PhD, former Assistant Secretary for Planning and Evaluation at the U.S. Department of Health and Human Services, and member of the NeuroRx Board of Directors. “The NRx leadership team draws upon more than 100 collective years of pharmaceutical development, science and business expertise to bring Breakthrough Therapies to the market.”
  19. forum rang 10 DeZwarteRidder 27 september 2021 15:43
    quote:

    eric_k4 schreef op 27 september 2021 14:17:

    ...GEM heeft nimmer geinvesteerd in NRXP, en hier wil ik het bij laten...

    Deze aansporing heeft geleid tot de door mij gewenste zichtbare informatie van GEM-NRXP, met dank daarvoor DZR!
    En nu mag je je excuses aanbieden.......!!
9.104 Posts
Pagina: «« 1 ... 425 426 427 428 429 ... 456 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee